The kinetics of phosphate (P) during a treatment of hemofiltration or hemodiafiltration follows a simple exponential law, and P in 90 min reaches a stationary level that remains constant until the end of the treatment. The theoretical compartmental model cannot be estimated by a dialytic treatment, but a simpler diffusive model may be considered. Once the stationary level is reached, the net flux of P from the inaccessible compartments to the accessible compartment may be estimated via the parameters obtained in the exponential model. Hemodiafiltration seems more efficient than hemofiltration in determining P clearance. Thus an efficiency index that accounts for the period in which P is eliminated from the accessible compartment has been formulated.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1525-1594.1993.tb00380.xDOI Listing

Publication Analysis

Top Keywords

hemofiltration hemodiafiltration
8
stationary level
8
accessible compartment
8
analysis phosphate
4
phosphate kinetics
4
kinetics hemofiltration
4
hemodiafiltration formulation
4
formulation efficiency
4
efficiency kinetics
4
kinetics phosphate
4

Similar Publications

Background: High blood pressure is a prevalent condition in patients with chronic kidney disease on hemodialysis. Adequate control of high blood pressure is essential to reducing deaths in this group. The present study aimed to observe mortality prospectively in a group of patients in hemodialysis and hemodiafiltration programs in whom the use of antihypertensives was optimized with the point-of-care dry weight (POC-DW) technique.

View Article and Find Full Text PDF

Water treatment-free prolonged intermittent kidney replacement therapy: A new approach for kidney replacement therapy in the ICU setting. A retrospective study.

J Crit Care

January 2025

AP-HP, Hôpital Louis Mourier, DMU ESPRIT, Service de Médecine Intensive Réanimation, F-92700 Colombes, France; Université Paris Cité, Medical school, F-75018 Paris, France; Université Paris Cité, INSERM UMR-S1151, CNRS UMR-S8253, Institut Necker Enfants Malades, F-75015 Paris, France. Electronic address:

The optimal modalities of kidney replacement therapy (KRT) in the ICU remain debated. Intermittent haemodialysis (IHD) and continuous veno-venous haemofiltration (CVVH) are the two main methods. Intermittent haemodialysis requires a water treatment system, which may not be available in all jurisdictions.

View Article and Find Full Text PDF

Real-world effectiveness of hemodialysis modalities: a retrospective cohort study.

BMC Nephrol

January 2025

Fresenius Medical Care Deutschland GmbH, Bad Homburg, Hessen, Germany.

Background: Results from the CONVINCE clinical trial suggest a 23% mortality risk reduction among patients receiving high-volume (> 23 L) hemodiafiltration. We assessed the real-world effectiveness of blood-based kidney replacement therapy (KRT) with hemodiafiltration vs. hemodialysis in a large, unselected patient population treated prior to and during the COVID-19 pandemic.

View Article and Find Full Text PDF

Various high-efficiency hemodialysis techniques exist, including different online high- volume hemodiafiltration (HDF) modes and expanded hemodialysis (HDx) utilizing dialyzers with medium cut-off (MCO) membranes. This study aimed to evaluate the efficacy of uremic toxin removal among four modalities: (I) HDx, (II) pre-dilution HDF (PRE-HDF), (III) mixed-dilution HDF (MIX-HDF), and (IV) post-dilution HDF (POST-HDF), each applied for 1 week in a randomized order. This research was a single-center, prospective, open-label, exploratory crossover study.

View Article and Find Full Text PDF
Article Synopsis
  • Fabry disease is an X-linked lysosomal disorder causing complications like kidney issues and challenges with drug elimination, prompting the need to study migalastat in patients with end-stage renal disease (ESRD) on dialysis.
  • This study tested a 123 mg dose of migalastat in ESRD patients compared to controls with normal kidney function, examining its pharmacokinetics, how well it's cleared during dialysis, and its tolerability.
  • Results showed that migalastat is largely removed by dialysis and suggested dosing regimens for ESRD patients that could maintain effective drug levels while minimizing accumulation in tissues.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!